More on CSLLY
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $20.00 |
|
|||
| Open | $20.38 | ||||
| 52 Wk High | $45.60 | ||||
| 52 Wk Low | $33.39 | ||||
| Day High | $20.38 | ||||
| Day Low | $20.17 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 120,133 | ||||
- CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)
- EU panel recommends revoking Tavneos marketing authorization
- CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union
- Jefferies Downgrades CSL Ltd. (CSL:AU) (CSLLY) to Hold
- CSL Ltd. (CSL:AU) (CSLLY) PT Lowered to AUD175 at UBS
- CSL Ltd. (CSL:AU) (CSLLY) PT Lowered to AUD205 at UBS
- CSL announces expansion of Illinois plasma therapy manufacturing facility
- Deutsche Bank Appointed as Successor Depositary Bank for the American Depositary Receipt Program of CSL Limited
- Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
- CSL Ltd. (CSL:AU) (CSLLY) PT Lowered to AUD225 at CLSA
Entities mentioned with CSLLY
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- AdCom | View Related Stories »
- Vanguard | View Related Stories »
- JPMorgan | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
